Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1
Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1
复制标题
DOI:
10.1182/blood.v98.5.1524
复制
发表时间:
2001-09-01
期刊:
影响因子:
20.3
通讯作者:
Boussiotis, VA
中科院分区:
文献类型:
--
作者:
Barata, JT;Cardoso, AA;Boussiotis, VA
In normal T-cell development interleukin-7 (IL-7) functions as an antiapoptotic factor by regulating bcl-2 expression in Immature thymocytes and mature T cells. Similar to what occurs in normal immature thymocytes, prevention of spontaneous apoptosis by IL-7 in precursor T-cell acute lymphoblastic leukemia (T-ALL) cells correlates with up-regulation of bcl-2. IL-7 is also implicated in leukemogenesis because IL-7 transgenic mice develop lymphoid malignancies, suggesting that IL-7 may regulate the generation and expansion of malignant cells. This study shows that in the presence of IL-7, T-ALL cells not only up-regulated bcl-2 expression and escaped apoptosis but also progressed In the cell cycle, resulting in sequential induction of cyclin D2 and cyclin A. Down-regulation of p27(kip1) was mandatory for IL-7-mediated cell cycle progression and temporally coincided with activation of cyclin-dependent kinase (cdk)4 and cdk2 and hyperphosphorylation of Rb. Strikingly, forced expression of P27(kip1) in T-ALL cells not only prevented cell cycle progression but also reversed IL-7-mediated up-regulation of bcl-2 and promotion of viability. These results show for the first time that a causative link between IL-7-mediated proliferation and p27(kip1) down-regulation exists in malignant T cells. Moreover, these results suggest that p27(kip1) may function as a tumor suppressor gene not only because it is a negative regulator of cell cycle progression but also because it Is associated with Induction of apoptosis of primary malignant cells. (C) 2001 by The American Society of Hematology.